{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T19:32:53Z","timestamp":1773516773975,"version":"3.50.1"},"reference-count":171,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T00:00:00Z","timestamp":1752710400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006769","name":"Russian Science Foundation","doi-asserted-by":"publisher","award":["24-25-20139"],"award-info":[{"award-number":["24-25-20139"]}],"id":[{"id":"10.13039\/501100006769","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>The emergence of a novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus closely related to SARS-CoV and officially known as Betacoronavirus pandemicum precipitated a substantial surge in vaccine development that culminated during the global COVID-19 pandemic. At present, there are dozens of vaccines for the prevention of SARS-CoV-2 being utilized across the globe. However, only 10 of these vaccines have been authorized by the World Health Organization (WHO). These include mRNA-based, viral vector, subunit and whole-virion inactivated vaccines. At the current end of the pandemic, there has been a decline in the global vaccination rate, both for the general population and for those most at risk of severe illness from the virus. This suggests that the effectiveness of the vaccines may be waning. The decline occurs alongside a decrease in testing and sequencing for SARS-CoV-2. Furthermore, the process of tracking viruses becomes increasingly complex, thereby providing a selective advantage for SARS-CoV-2 and allowing it to evolve stealthily. In this review, we provide a comprehensive overview of viral evolution and vaccine development. We also discuss ways to overcome viral variability and test universal vaccines for all SARS-CoV-2 variants.<\/jats:p>","DOI":"10.3390\/vaccines13070761","type":"journal-article","created":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T11:25:17Z","timestamp":1752751517000},"page":"761","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Adaptation of the Vaccine Prophylaxis Strategy to Variants of the SARS-CoV-2 Virus"],"prefix":"10.3390","volume":"13","author":[{"given":"Sofia M.","family":"Gulova","sequence":"first","affiliation":[{"name":"Department of Immunobiology and Biomedicine, Sirius University of Science and Technology, 354349 Sirius, Krasnodarsky Krai, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uliana S.","family":"Veselkina","sequence":"additional","affiliation":[{"name":"Department of Immunobiology and Biomedicine, Sirius University of Science and Technology, 354349 Sirius, Krasnodarsky Krai, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irina V.","family":"Astrakhantseva","sequence":"additional","affiliation":[{"name":"Department of Immunobiology and Biomedicine, Sirius University of Science and Technology, 354349 Sirius, Krasnodarsky Krai, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,7,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/s41564-020-0695-z","article-title":"The Species Severe Acute Respiratory Syndrome-Related Coronavirus: Classifying 2019-NCoV and Naming It SARS-CoV-2","volume":"5","author":"Gorbalenya","year":"2020","journal-title":"Nat. Microbiol."},{"key":"ref_2","unstructured":"National Library for Medicine, Available online: https:\/\/www.ncbi.nlm.nih.gov\/datasets\/taxonomy\/3418604\/."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Soheili, M., Khateri, S., Moradpour, F., Mohammadzedeh, P., Zareie, M., Mortazavi, S.M.M., Manifar, S., Kohan, H.G., and Moradi, Y. (2023). The Efficacy and Effectiveness of COVID-19 Vaccines around the World: A Mini-Review and Meta-Analysis. Ann. Clin. Microbiol. Antimicrob., 22.","DOI":"10.1186\/s12941-023-00594-y"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Sharif, N., Alzahrani, K.J., Ahmed, S.N., and Dey, S.K. (2021). Efficacy, Immunogenicity and Safety of COVID-19 Vaccines: A Systematic Review and Meta-Analysis. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.714170"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e00127-20","DOI":"10.1128\/JVI.00127-20","article-title":"Receptor Recognition by the Novel Coronavirus from Wuhan: An Analysis Based on Decade-Long Structural Studies of SARS Coronavirus","volume":"94","author":"Wan","year":"2020","journal-title":"J. Virol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.cell.2020.02.058","article-title":"Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein","volume":"181","author":"Walls","year":"2020","journal-title":"Cell"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/s41586-020-2380-z","article-title":"Human Neutralizing Antibodies Elicited by SARS-CoV-2 Infection","volume":"584","author":"Ju","year":"2020","journal-title":"Nature"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Papageorgiou, A.C., and Mohsin, I. (2020). The SARS-CoV-2 Spike Glycoprotein as a Drug and Vaccine Target: Structural Insights into Its Complexes with ACE2 and Antibodies. Cells, 9.","DOI":"10.3390\/cells9112343"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.crimmu.2022.08.005","article-title":"From Alpha to Omicron: The Response of T Cells","volume":"3","author":"Grifoni","year":"2022","journal-title":"Curr. Res. Immunol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Gushchin, V.A., Pochtovyi, A.A., Kustova, D.D., Ogarkova, D.A., Tarnovetskii, I.Y., Belyaeva, E.D., Divisenko, E.V., Vasilchenko, L.A., Shidlovskaya, E.V., and Kuznetsova, N.A. (2022). Dynamics of SARS-CoV-2 Major Genetic Lineages in Moscow in the Context of Vaccine Prophylaxis. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232314670"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"ofaf181","DOI":"10.1093\/ofid\/ofaf181","article-title":"COVID-19 Reinfections in the City of S\u00e3o Paulo, Brazil: Prevalence and Socioeconomic Factors","volume":"12","author":"Malheiro","year":"2025","journal-title":"Open Forum Infect. Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1002\/mco2.72","article-title":"A Bivalent Recombinant Vaccine Targeting the S1 Protein Induces Neutralizing Antibodies against Both SARS-CoV-2 Variants and Wild-Type of the Virus","volume":"2","author":"He","year":"2021","journal-title":"MedComm"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Heidary, M., Kaviar, V.H., Shirani, M., Ghanavati, R., Motahar, M., Sholeh, M., Ghahramanpour, H., and Khoshnood, S. (2022). A Comprehensive Review of the Protein Subunit Vaccines Against COVID-19. Front. Microbiol., 13.","DOI":"10.3389\/fmicb.2022.927306"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"4781","DOI":"10.7150\/ijbs.72109","article-title":"Cross-Variant Protection against SARS-CoV-2 Infection in Hamsters Immunized with Monovalent and Bivalent Inactivated Vaccines","volume":"18","author":"Ye","year":"2022","journal-title":"Int. J. Biol. Sci."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1056\/NEJMoa2208343","article-title":"A Bivalent Omicron-Containing Booster Vaccine against Covid-19","volume":"387","author":"Chalkias","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Liu, B., Wang, Z., Lu, S., Qi, Z., Zhang, Z., Luan, J., and Ba, J. (2025). Monitoring Reported SARS-CoV-2 Variants to Assess the Status of COVID-19 Epidemics in the Low Epidemic State. Sci. Rep., 15.","DOI":"10.1038\/s41598-025-91308-1"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Awasthi, S., Dehkharghani, M.Z., and Fudolig, M. (2025). Emergence to Dominance: Estimating Time to Dominance of SARS-CoV-2 Variants Using Nonlinear Statistical Models. PLoS ONE, 20.","DOI":"10.1371\/journal.pone.0311459"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1186\/s12985-022-01951-7","article-title":"Mutations in SARS-CoV-2 Structural Proteins: A Global Analysis","volume":"19","author":"Abavisani","year":"2022","journal-title":"Virol. J."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"105699","DOI":"10.1016\/j.micpath.2022.105699","article-title":"Unique Mutations in SARS-CoV-2 Omicron Subvariants\u2019 Non-Spike Proteins: Potential Impacts on Viral Pathogenesis and Host Immune Evasion","volume":"170","author":"Hossain","year":"2022","journal-title":"Microb. Pathog."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Koyama, T., Weeraratne, D., Snowdon, J.L., and Parida, L. (2020). Emergence of Drift Variants That May Affect COVID-19 Vaccine Development and Antibody Treatment. Pathogens, 9.","DOI":"10.20944\/preprints202004.0024.v1"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"495","DOI":"10.2471\/BLT.20.253591","article-title":"Variant Analysis of SARS-CoV-2 Genomes","volume":"98","author":"Koyama","year":"2020","journal-title":"Bull. World Health Organ."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41586-020-2895-3","article-title":"Spike Mutation D614G Alters SARS-CoV-2 Fitness","volume":"592","author":"Plante","year":"2021","journal-title":"Nature"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.cell.2020.06.043","article-title":"Tracking Changes in SARS-CoV-2 Spike: Evidence That D614G Increases Infectivity of the COVID-19 Virus","volume":"182","author":"Korber","year":"2020","journal-title":"Cell"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1126\/science.abe8499","article-title":"SARS-CoV-2 D614G Variant Exhibits Efficient Replication Ex Vivo and Transmission in Vivo","volume":"370","author":"Hou","year":"2020","journal-title":"Science"},{"key":"ref_25","unstructured":"Morbidity and Mortality Weekly Report (MMWR), Available online: https:\/\/www.cdc.gov\/mmwr\/volumes\/70\/wr\/mm7003e2.htm?utm_source=mp-fotoscapes#suggestedcitation."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e108944","DOI":"10.15252\/embj.2021108944","article-title":"SARS-CoV-2 Alpha, Beta, and Delta Variants Display Enhanced Spike-mediated Syncytia Formation","volume":"40","author":"Rajah","year":"2021","journal-title":"EMBO J."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"a041390","DOI":"10.1101\/cshperspect.a041390","article-title":"The Evolution and Biology of SARS-CoV-2 Variants","volume":"12","author":"Telenti","year":"2022","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"4598","DOI":"10.1038\/s41467-021-24909-9","article-title":"Neutralizing Activity of Sputnik V Vaccine Sera against SARS-CoV-2 Variants","volume":"12","author":"Ikegame","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1126\/science.abg6105","article-title":"Neutralization of SARS-CoV-2 Lineage B.1.1.7 Pseudovirus by BNT162b2 Vaccine\u2013Elicited Human Sera","volume":"371","author":"Muik","year":"2021","journal-title":"Science"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.chom.2021.03.002","article-title":"SARS-CoV-2 Variant B.1.1.7 Is Susceptible to Neutralizing Antibodies Elicited by Ancestral Spike Vaccines","volume":"29","author":"Shen","year":"2021","journal-title":"Cell Host Microbe"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/S1473-3099(21)00287-5","article-title":"Serum Neutralising Activity against SARS-CoV-2 Variants Elicited by CoronaVac","volume":"21","author":"Chen","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"101606","DOI":"10.1016\/j.bjid.2021.101606","article-title":"The Impact of Spike Mutated Variants of SARS-CoV2 [Alpha, Beta, Gamma, Delta, and Lambda] on the Efficacy of Subunit Recombinant Vaccines","volume":"25","author":"Mohammadi","year":"2021","journal-title":"Brazilian J. Infect. Dis."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41586-020-2895-3","article-title":"Spike Mutation D614G AltersSARS-CoV-2 Fitness and Neutralization Susceptibility","volume":"592","author":"Plante","year":"2020","journal-title":"Nature"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41580-021-00418-x","article-title":"Mechanisms of SARS-CoV-2 Entry into Cells","volume":"23","author":"Jackson","year":"2022","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/s41579-023-00878-2","article-title":"The Evolution of SARS-CoV-2","volume":"21","author":"Markov","year":"2023","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"7345","DOI":"10.1038\/s41467-021-27350-0","article-title":"Conformational Dynamics of the Beta and Kappa SARS-CoV-2 Spike Proteins and Their Complexes with ACE2 Receptor Revealed by Cryo-EM","volume":"12","author":"Wang","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"103939","DOI":"10.1016\/j.isci.2022.103939","article-title":"Impact of New Variants on SARS-CoV-2 Infectivity and Neutralization: A Molecular Assessment of the Alterations in the Spike-Host Protein Interactions","volume":"25","author":"Cheng","year":"2022","journal-title":"iScience"},{"key":"ref_38","unstructured":"Padilha, D.A., Benetti Filho, V., Moreira, R.S., Soratto, T.A., Maia, G.A., Christoff, A.P., Barazzetti, F.H., Sch\u00f6rner, M.A., Ferrari, F.L., and Martins, C.L. (2022). Emergence of Two Distinct SARS-CoV-2 Gamma Variants and the Rapid Spread of P.1-like-II SARS-CoV-2 during the Second Wave of COVID-19 in Santa Catarina, Southern Brazil. Viruses, 14."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/s41392-022-00941-z","article-title":"SARS-CoV-2 Spike L452R Mutation Increases Omicron Variant Fusogenicity and Infectivity as Well as Host Glycolysis","volume":"7","author":"Zhang","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/s41586-021-03777-9","article-title":"Reduced Sensitivity of SARS-CoV-2 Variant Delta to Antibody Neutralization","volume":"596","author":"Planas","year":"2021","journal-title":"Nature"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e2200592119","DOI":"10.1073\/pnas.2200592119","article-title":"Omicron Mutations Enhance Infectivity and Reduce Antibody Neutralization of SARS-CoV-2 Virus-like Particles","volume":"119","author":"Syed","year":"2022","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/j.ijbiomac.2022.07.254","article-title":"Omicron (B.1.1.529)\u2014A New Heavily Mutated Variant: Mapped Location and Probable Properties of Its Mutations with an Emphasis on S-Glycoprotein","volume":"219","author":"Chakraborty","year":"2022","journal-title":"Int. J. Biol. Macromol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1038\/s41467-024-45075-8","article-title":"Omicron Spike Confers Enhanced Infectivity and Interferon Resistance to SARS-CoV-2 in Human Nasal Tissue","volume":"15","author":"Shi","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"e2381","DOI":"10.1002\/rmv.2381","article-title":"Evolution of the SARS-CoV-2 Omicron Variants BA.1 to BA.5: Implications for Immune Escape and Transmission","volume":"32","author":"Shrestha","year":"2022","journal-title":"Rev. Med. Virol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2952","DOI":"10.1016\/j.cell.2022.06.023","article-title":"Structural Basis of Human ACE2 Higher Binding Affinity to Currently Circulating Omicron SARS-CoV-2 Sub-Variants BA.2 and BA.1.1","volume":"185","author":"Li","year":"2022","journal-title":"Cell"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"e01011-23","DOI":"10.1128\/jvi.01011-23","article-title":"Multiple Mutations of SARS-CoV-2 Omicron BA.2 Variant Orchestrate Its Virological Characteristics","volume":"97","author":"Izumi","year":"2023","journal-title":"J. Virol."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Kannan, S.R., Spratt, A.N., Sharma, K., Goyal, R., S\u00f6nnerborg, A., Apparsundaram, S., Lorson, C.L., Byrareddy, S.N., and Singh, K. (2022). Complex Mutation Pattern of Omicron BA.2: Evading Antibodies without Losing Receptor Interactions. Int. J. Mol. Sci., 23.","DOI":"10.20944\/preprints202204.0120.v1"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1097\/JS9.0000000000000246","article-title":"The SARS-CoV-2 Omicron Recombinant Subvariants XBB, XBB.1, and XBB.1.5 Are Expanding Rapidly with Unique Mutations, Antibody Evasion, and Immune Escape Properties\u2014An Alarming Global Threat of a Surge in COVID-19 Cases Again?","volume":"109","author":"Chakraborty","year":"2023","journal-title":"Int. J. Surg."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.1038\/s41467-023-38435-3","article-title":"Virological Characteristics of the SARS-CoV-2 XBB Variant Derived from Recombination of Two Omicron Subvariants","volume":"14","author":"Tamura","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Giancotti, R., Lomoio, U., Puccio, B., Tradigo, G., Vizza, P., Torti, C., Veltri, P., and Guzzi, P.H. (2024). The Omicron XBB.1 Variant and Its Descendants: Genomic Mutations, Rapid Dissemination and Notable Characteristics. Biology, 13.","DOI":"10.3390\/biology13020090"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Criscuolo, E., Giuliani, B., Castelli, M., Cavallaro, M., Sisti, S., Burioni, R., Ferrari, D., Mancini, N., Locatelli, M., and Clementi, N. (2024). Single Spike Mutation Differentiating XBB.1 and XBB.1.5 Enhances SARS-CoV-2 Cell-to-Cell Transmission and Facilitates Serum-Mediated Enhancement. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1501200"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/s41392-023-01712-0","article-title":"SARS-CoV-2 Omicron Subvariant BA.2.86: Limited Potential for Global Spread","volume":"8","author":"Wang","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.chom.2024.01.001","article-title":"Virological Characteristics of the SARS-CoV-2 BA.2.86 Variant","volume":"32","author":"Tamura","year":"2024","journal-title":"Cell Host Microbe"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"8728","DOI":"10.1038\/s41467-024-53033-7","article-title":"Lineage-Specific Pathogenicity, Immune Evasion, and Virological Features of SARS-CoV-2 BA.2.86\/JN.1 and EG.5.1\/HK.3","volume":"15","author":"Liu","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Selvavinayagam, S.T., Sankar, S., Yong, Y.K., Murugesan, A., Suvaithenamudhan, S., Hemashree, K., Rajeshkumar, M., Kumaresan, A., Pandey, R.P., and Shanmugam, S. (2024). Emergence of SARS-CoV-2 Omicron Variant JN.1 in Tamil Nadu, India\u2014Clinical Characteristics and Novel Mutations. Sci. Rep., 14.","DOI":"10.1038\/s41598-024-68678-z"},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Focosi, D., Spezia, P.G., Gueli, F., and Maggi, F. (2024). The Era of the FLips: How Spike Mutations L455F and F456L (and A475V) Are Shaping SARS-CoV-2 Evolution. Viruses, 16.","DOI":"10.3390\/v16010003"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"114520","DOI":"10.1016\/j.celrep.2024.114520","article-title":"Neutralization Escape, Infectivity, and Membrane Fusion of JN.1-Derived SARS-CoV-2 SLip, FLiRT, and KP.2 Variants","volume":"44","author":"Li","year":"2024","journal-title":"Cell Rep."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Li, P., Faraone, J.N., Hsu, C.C., Chamblee, M., Zheng, Y.-M., Carlin, C., Bednash, J.S., Horowitz, J.C., Mallampalli, R.K., and Saif, L.J. (2024). Characteristics of JN.1-Derived SARS-CoV-2 Subvariants SLip, FLiRT, and KP.2 in Neutralization Escape, Infectivity and Membrane Fusion. bioRxiv Prepr. Serv. Biol., preprint.","DOI":"10.1101\/2024.05.20.595020"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41541-024-01016-6","article-title":"Neutralization of SARS-CoV-2 KP.1, KP.1.1, KP.2 and KP.3 by Human and Murine Sera","volume":"9","author":"Xu","year":"2024","journal-title":"Npj Vaccines"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"e416","DOI":"10.1016\/S1473-3099(24)00298-6","article-title":"Virological Characteristics of the SARS-CoV-2 KP.2 Variant","volume":"24","author":"Kaku","year":"2024","journal-title":"Lancet Infect. Dis."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.1016\/S1473-3099(24)00738-2","article-title":"Enhanced Immune Evasion of SARS-CoV-2 Variants KP.3.1.1 and XEC through N-Terminal Domain Mutations","volume":"25","author":"Liu","year":"2025","journal-title":"Lancet Infect. Dis."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"e00242-25","DOI":"10.1128\/jvi.00242-25","article-title":"Role of Glycosylation Mutations at the N-Terminal Domain of SARS-CoV-2 XEC Variant in Immune Evasion, Cell-Cell Fusion, and Spike Stability","volume":"99","author":"Li","year":"2025","journal-title":"J. Virol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1038\/s41586-021-03402-9","article-title":"Detection of a SARS-CoV-2 Variant of Concern in South Africa","volume":"592","author":"Tegally","year":"2021","journal-title":"Nature"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1093\/infdis\/jiab355","article-title":"Limited Neutralization of Authentic Severe Acute Respiratory Syndrome Coronavirus 2 Variants Carrying E484K In Vitro","volume":"224","author":"Widera","year":"2021","journal-title":"J. Infect. Dis."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1038\/s41591-021-01446-y","article-title":"MRNA-1273 COVID-19 Vaccine Effectiveness against the B.1.1.7 and B.1.351 Variants and Severe COVID-19 Disease in Qatar","volume":"27","author":"Chemaitelly","year":"2021","journal-title":"Nat. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"101190","DOI":"10.1016\/j.eclinm.2021.101190","article-title":"Effectiveness of BNT162b2 MRNA COVID-19 Vaccine against SARS-CoV-2 Variant Beta (B.1.351) among Persons Identified through Contact Tracing in Israel: A Prospective Cohort Study","volume":"42","author":"Singer","year":"2021","journal-title":"eClinicalMedicine"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1056\/NEJMoa2102214","article-title":"Efficacy of the ChAdOx1 NCoV-19 Covid-19 Vaccine against the B.1.351 Variant","volume":"384","author":"Madhi","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1016\/j.cell.2021.02.037","article-title":"Evidence of Escape of SARS-CoV-2 Variant B.1.351 from Natural and Vaccine-Induced Sera","volume":"184","author":"Zhou","year":"2021","journal-title":"Cell"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1126\/science.abh2644","article-title":"Genomics and Epidemiology of the P.1 SARS-CoV-2 Lineage in Manaus, Brazil","volume":"821","author":"Faria","year":"2021","journal-title":"Science"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.jinf.2021.09.005","article-title":"Clinical features of COVID-19 by SARS-CoV-2 Gamma variant: A prospective cohort study of vaccinated and unvaccinated healthcare workers","volume":"84","author":"Borges","year":"2022","journal-title":"J. Infect."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s43856-022-00108-5","article-title":"Impact of SARS-CoV-2 Gamma Lineage Introduction and COVID-19 Vaccination on the epidemiological landscape of a Brazilian city","volume":"2","author":"Banho","year":"2022","journal-title":"Commun. Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41467-021-26459-6","article-title":"Effectiveness of ChAdOx1 Vaccine in Older Adults","volume":"12","author":"Hitchings","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"ofab143","DOI":"10.1093\/ofid\/ofab143","article-title":"CD8+ T-Cell Responses in COVID-19 Convalescent Individuals Target Conserved Epitopes From Multiple Prominent SARS-CoV-2 Circulating Variants","volume":"8","author":"Redd","year":"2021","journal-title":"Open Forum Infect. Dis."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S1473-3099(22)00001-9","article-title":"Generation Time of the Alpha and Delta SARS-CoV-2 Variants: An Epidemiological Analysis","volume":"22","author":"Hart","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"110829","DOI":"10.1016\/j.celrep.2022.110829","article-title":"Delta Spike P681R Mutation Enhances SARS-CoV-2 Fitness over Alpha Variant","volume":"39","author":"Liu","year":"2022","journal-title":"Cell Rep."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1007\/s15010-024-02223-y","article-title":"SARS-CoV-2 Journey: From Alpha Variant to Omicron and Its Sub-Variants","volume":"52","author":"Hattab","year":"2024","journal-title":"Infection"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1038\/s41591-021-01548-7","article-title":"Effect of Delta Variant on Viral Burden and Vaccine Effectiveness against New SARS-CoV-2 Infections in the UK","volume":"27","author":"Pouwels","year":"2021","journal-title":"Nat. Med."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1056\/NEJMoa2116597","article-title":"Effect of Covid-19 Vaccination on Transmission of Alpha and Delta Variants","volume":"386","author":"Eyre","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1038\/s41564-022-01161-5","article-title":"Inactivated Whole-Virion Vaccine BBV152\/Covaxin Elicits Robust Cellular Immune Memory to SARS-CoV-2 and Variants of Concern","volume":"7","author":"Vikkurthi","year":"2022","journal-title":"Nat. Microbiol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"199392","DOI":"10.1016\/j.virusres.2024.199392","article-title":"A Systematic Mutation Analysis of 13 Major SARS-CoV-2 Variants","volume":"345","author":"Bai","year":"2024","journal-title":"Virus Res."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1038\/s41467-022-30895-3","article-title":"Duration of MRNA Vaccine Protection against SARS-CoV-2 Omicron BA.1 and BA.2 Subvariants in Qatar","volume":"13","author":"Chemaitelly","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/j.chom.2022.05.001","article-title":"Antibody Evasion of SARS-CoV-2 Omicron BA.1, BA.1.1, BA.2, and BA.3 Sub-Lineages","volume":"30","author":"Ai","year":"2022","journal-title":"Cell Host Microbe"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.medj.2022.04.013","article-title":"Safety and Immunogenicity of the Pfizer\/BioNTech SARS-CoV-2 MRNA Third Booster Vaccine Dose against the BA.1 and BA.2 Omicron Variants","volume":"3","author":"Seki","year":"2022","journal-title":"Med"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1002\/jmv.27644","article-title":"Third Dose of SARS-CoV-2 Vaccine: A Systematic Review of 30 Published Studies","volume":"94","author":"Petrelli","year":"2022","journal-title":"J. Med. Virol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/S1473-3099(23)00189-5","article-title":"Bivalent Omicron (BA.1) Booster Vaccination against SARS-CoV-2","volume":"23","author":"Vasin","year":"2023","journal-title":"Lancet Infect. Dis."},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Bhiman, J.N., Richardson, S.I., Lambson, B.E., Kgagudi, P., Mzindle, N., Kaldine, H., Crowther, C., Gray, G., Bekker, L.-G., and Koen, A. (2023). Novavax NVX-COV2373 Triggers Neutralization of Omicron Sub-Lineages. Sci. Rep., 13.","DOI":"10.1038\/s41598-023-27698-x"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.cell.2023.12.026","article-title":"Immune Evasion, Infectivity, and Fusogenicity of SARS-CoV-2 BA.2.86 and FLip Variants","volume":"187","author":"Qu","year":"2024","journal-title":"Cell"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"112443","DOI":"10.1016\/j.celrep.2023.112443","article-title":"Enhanced Evasion of Neutralizing Antibody Response by Omicron XBB.1.5, CH.1.1, and CA.3.1 Variants","volume":"42","author":"Qu","year":"2023","journal-title":"Cell Rep."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.chom.2023.11.012","article-title":"Enhanced Neutralization of SARS-CoV-2 Variant BA.2.86 and XBB Sub-Lineages by a Tetravalent COVID-19 Vaccine Booster","volume":"32","author":"Wang","year":"2024","journal-title":"Cell Host Microbe"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"10778","DOI":"10.1038\/s41467-024-55087-z","article-title":"Trivalent Recombinant Protein Vaccine Induces Cross-Neutralization against XBB Lineage and JN.1 Subvariants: Preclinical and Phase 1 Clinical Trials","volume":"15","author":"Yang","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1056\/NEJMc2029813","article-title":"Neutralization of BA.4\u2013BA.5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 with Bivalent Vaccine","volume":"388","author":"Klotz","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"6255","DOI":"10.1038\/s41467-024-49832-7","article-title":"Efficacy of the Tetravalent Protein COVID-19 Vaccine, SCTV01E: A Phase 3 Double-Blind, Randomized, Placebo-Controlled Trial","volume":"15","author":"Zhang","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1002\/jmv.27697","article-title":"Current Evidence on Efficacy of COVID-19 Booster Dose Vaccination against the Omicron Variant: A Systematic Review","volume":"94","author":"Chenchula","year":"2022","journal-title":"J. Med. Virol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.chom.2024.01.014","article-title":"XBB.1.5 Monovalent MRNA Vaccine Booster Elicits Robust Neutralizing Antibodies against XBB Subvariants and JN.1","volume":"32","author":"Wang","year":"2024","journal-title":"Cell Host Microbe"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/S1473-3099(24)00670-4","article-title":"Immunogenicity and Safety of a Monovalent Omicron XBB.1.5 SARS-CoV-2 Recombinant Spike Protein Vaccine as a Heterologous Booster Dose in US Adults: Interim Analysis of a Single-Arm Phase 2\/3 Study","volume":"25","author":"Alves","year":"2025","journal-title":"Lancet Infect. Dis."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.chom.2023.12.003","article-title":"Post-Pandemic Memory T Cell Response to SARS-CoV-2 Is Durable, Broadly Targeted, and Cross-Reactive to the Hypermutated BA.2.86 Variant","volume":"32","author":"Nesamari","year":"2024","journal-title":"Cell Host Microbe"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1038\/s41586-024-08315-x","article-title":"Evolving Antibody Response to SARS-CoV-2 Antigenic Shift from XBB to JN.1","volume":"637","author":"Jian","year":"2025","journal-title":"Nature"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"e82","DOI":"10.1016\/S1473-3099(23)00813-7","article-title":"Virological Characteristics of the SARS-CoV-2 JN.1 Variant","volume":"24","author":"Kaku","year":"2024","journal-title":"Lancet Infect. Dis."},{"key":"ref_99","unstructured":"CDC COVID Data Tracker, Available online: https:\/\/covid.cdc.gov\/covid-data-tracker\/#variant-summary."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"e313","DOI":"10.1016\/S2666-5247(23)00373-7","article-title":"Characteristics of the SARS-CoV-2 Omicron HK.3 Variant Harbouring the FLip Substitution","volume":"5","author":"Kosugi","year":"2024","journal-title":"Lancet Microbe"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/S1473-3099(24)00603-0","article-title":"Humoral Immunity after MRNA SARS-CoV-2 Omicron JN.1 Vaccination","volume":"24","author":"Happle","year":"2024","journal-title":"Lancet Infect. Dis."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1016\/S1473-3099(24)00810-7","article-title":"Antiviral Humoral Immunity Induced by JN.1 Monovalent MRNA Vaccines against SARS-CoV-2 Omicron Subvariants Including JN.1, KP.3.1.1, and XEC","volume":"25","author":"Uriu","year":"2025","journal-title":"Lancet Infect. Dis."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"ofad075","DOI":"10.1093\/ofid\/ofad075","article-title":"Population-Level Effectiveness of an Inactivated Whole-Virion COVID-19 Vaccine: A Test Negative Case-Control Study in the Dominican Republic","volume":"10","author":"Miric","year":"2023","journal-title":"Open Forum Infect. Dis."},{"key":"ref_104","first-page":"100025","article-title":"Effectiveness of CoronaVac among Healthcare Workers in the Setting of High SARS-CoV-2 Gamma Variant Transmission in Manaus, Brazil: A Test-Negative Case-Control Study","volume":"1","author":"Hitchings","year":"2021","journal-title":"Lancet Reg. Health Am."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1080\/22221751.2021.1969291","article-title":"Effectiveness of Inactivated SARS-CoV-2 Vaccines against the Delta Variant Infection in Guangzhou: A Test-Negative Case\u2013Control Real-World Study","volume":"10","author":"Li","year":"2021","journal-title":"Emerg. Microbes Infect."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1111\/imm.13535","article-title":"Comparison of the Immunogenicity of Five COVID-19 Vaccines in Sri Lanka","volume":"167","author":"Jeewandara","year":"2022","journal-title":"Immunology"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"100788","DOI":"10.1016\/j.lanwpc.2023.100788","article-title":"Efficacy and Effectiveness of Inactivated Vaccines against Symptomatic COVID-19, Severe COVID-19, and COVID-19 Clinical Outcomes in the General Population: A Systematic Review and Meta-Analysis","volume":"37","author":"Law","year":"2023","journal-title":"Lancet Reg. Health West. Pacific"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2107715","article-title":"Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile","volume":"385","author":"Jara","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Svetlova, J., Gustin, D., Manuvera, V., Shirokov, D., Shokina, V., Prusakov, K., Aldarov, K., Kharlampieva, D., Matyushkina, D., and Bespyatykh, J. (2022). Microarray Profiling of Vaccination-Induced Antibody Responses to SARS-CoV-2 Variants of Interest and Concern. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232113220"},{"key":"ref_110","doi-asserted-by":"crossref","unstructured":"Leung, D., Mu, X., Duque, J.S.R., Cheng, S.M.S., Wang, M., Zhang, W., Zhang, Y., Tam, I.Y.S., Lee, T.S.S., and Lam, J.H.Y. (2022). Safety and Immunogenicity of 3 Doses of BNT162b2 and CoronaVac in Children and Adults with Inborn Errors of Immunity. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.982155"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/s41541-023-00731-w","article-title":"Polyfunctional CD4 T-Cells Correlating with Neutralising Antibody Is a Hallmark of COVISHIELDTM and COVAXIN\u00ae Induced Immunity in COVID-19 Exposed Indians","volume":"8","author":"Rakshit","year":"2023","journal-title":"Npj Vaccines"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"e2350664","DOI":"10.1002\/eji.202350664","article-title":"Inactivated Whole Virion Vaccine Protects K18-HACE2 Tg Mice against the Omicron SARS-CoV-2 Variant via Cross-Reactive T Cells and Nonneutralizing Antibody Responses","volume":"54","author":"Kruglov","year":"2024","journal-title":"Eur. J. Immunol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1056\/NEJMp2118468","article-title":"Universal Coronavirus Vaccines\u2014An Urgent Need","volume":"386","author":"Morens","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1126\/science.abj3321","article-title":"Broad Betacoronavirus Neutralization by a Stem Helix\u2013Specific Human Antibody","volume":"373","author":"Pinto","year":"2021","journal-title":"Science"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1126\/science.abq3773","article-title":"Broadly Neutralizing Antibodies Target the Coronavirus Fusion Peptide","volume":"377","author":"Dacon","year":"2022","journal-title":"Science"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1007\/s10875-021-00997-6","article-title":"Serologic Cross-Reactivity of SARS-CoV-2 with Endemic and Seasonal Betacoronaviruses","volume":"41","author":"Hicks","year":"2021","journal-title":"J. Clin. Immunol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"100189","DOI":"10.1016\/j.xcrm.2020.100189","article-title":"Epitope-Resolved Profiling of the SARS-CoV-2 Antibody Response Identifies Cross-Reactivity with Endemic Human Coronaviruses","volume":"2","author":"Ladner","year":"2021","journal-title":"Cell Reports Med."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/1348-0421.12945","article-title":"Proteolytic Activation of SARS-CoV-2 Spike Protein","volume":"66","author":"Takeda","year":"2022","journal-title":"Microbiol. Immunol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/s41392-023-01472-x","article-title":"Targetable Elements in SARS-CoV-2 S2 Subunit for the Design of Pan-Coronavirus Fusion Inhibitors and Vaccines","volume":"8","author":"Guo","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_120","doi-asserted-by":"crossref","unstructured":"Hatmal, M.M., Alshaer, W., Al-Hatamleh, M.A.I., Hatmal, M., Smadi, O., Taha, M.O., Oweida, A.J., Boer, J.C., Mohamud, R., and Plebanski, M. (2020). Comprehensive Structural and Molecular Comparison of Spike Proteins of SARS-CoV-2, SARS-CoV and MERS-CoV, and Their Interactions with ACE2. Cells, 9.","DOI":"10.3390\/cells9122638"},{"key":"ref_121","doi-asserted-by":"crossref","unstructured":"Shah, P., Canziani, G.A., Carter, E.P., and Chaiken, I. (2021). The Case for S2: The Potential Benefits of the S2 Subunit of the SARS-CoV-2 Spike Protein as an Immunogen in Fighting the COVID-19 Pandemic. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.637651"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1007\/s11427-023-2410-5","article-title":"A Pan-Coronavirus Peptide Inhibitor Prevents SARS-CoV-2 Infection in Mice by Intranasal Delivery","volume":"66","author":"Wu","year":"2023","journal-title":"Sci. China Life Sci."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"e28641","DOI":"10.1002\/jmv.28641","article-title":"SARS-CoV-2 Omicron XBB Subvariants Exhibit Enhanced Fusogenicity and Substantial Immune Evasion in Elderly Population, but High Sensitivity to Pan-Coronavirus Fusion Inhibitors","volume":"95","author":"Xia","year":"2023","journal-title":"J. Med. Virol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"e666","DOI":"10.1002\/mco2.666","article-title":"Development of Potent Pan-Coronavirus Fusion Inhibitors with a New Design Strategy","volume":"5","author":"Zhu","year":"2024","journal-title":"MedComm"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/s41423-020-0374-2","article-title":"Fusion Mechanism of 2019-NCoV and Fusion Inhibitors Targeting HR1 Domain in Spike Protein","volume":"17","author":"Xia","year":"2020","journal-title":"Cell. Mol. Immunol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"2244084","DOI":"10.1080\/22221751.2023.2244084","article-title":"An Engineered Recombinant Protein Containing Three Structural Domains in SARS-CoV-2 S2 Protein Has Potential to Act as a Pan-Human Coronavirus Entry Inhibitor or Vaccine Antigen","volume":"12","author":"Wang","year":"2023","journal-title":"Emerg. Microbes Infect."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"100313","DOI":"10.1016\/j.xcrm.2021.100313","article-title":"Cross-Reactive Coronavirus Antibodies with Diverse Epitope Specificities and Fc Effector Functions","volume":"2","author":"Shiakolas","year":"2021","journal-title":"Cell Reports Med."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"e01991-20","DOI":"10.1128\/mBio.01991-20","article-title":"S Protein-Reactive IgG and Memory B Cell Production after Human SARS-CoV-2 Infection Includes Broad Reactivity to the S2 Subunit","volume":"11","author":"Embong","year":"2020","journal-title":"MBio"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-020-2598-9","article-title":"SARS-CoV-2-Reactive T Cells in Healthy Donors and Patients with COVID-19","volume":"587","author":"Braun","year":"2020","journal-title":"Nature"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1126\/science.abe1107","article-title":"Preexisting and de Novo Humoral Immunity to SARS-CoV-2 in Humans","volume":"370","author":"Ng","year":"2020","journal-title":"Science"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"e70330","DOI":"10.7554\/eLife.70330","article-title":"Cross-Reactive Antibodies after Sars-Cov-2 Infection and Vaccination","volume":"10","author":"Grobben","year":"2021","journal-title":"Elife"},{"key":"ref_132","doi-asserted-by":"crossref","unstructured":"Tsugawa, Y., Furukawa, K., Ise, T., Takayama, M., Ota, T., Kuroda, T., Shano, S., Hashimoto, T., Konishi, H., and Ishihara, T. (2024). Discovery of Anti-SARS-CoV-2 S2 Protein Antibody CV804 with Broad-Spectrum Reactivity with Various Beta Coronaviruses and Analysis of Its Pharmacological Properties in Vitro and in Vivo. PLoS ONE, 19.","DOI":"10.1101\/2024.02.28.582480"},{"key":"ref_133","doi-asserted-by":"crossref","unstructured":"Felbinger, N., Trudil, D., Loomis, L., Ascione, R., Siragusa, G., Haba, S., Rastogi, S., Mucci, A., Claycomb, M., and Snowberger, S. (2023). Epitope Mapping of SARS-CoV-2 Spike Protein Differentiates the Antibody Binding Activity in Vaccinated and Infected Individuals. Front. Virol., 3.","DOI":"10.3389\/fviro.2023.988109"},{"key":"ref_134","doi-asserted-by":"crossref","unstructured":"Forni, D., Filippi, G., Cagliani, R., De Gioia, L., Pozzoli, U., Al-Daghri, N., Clerici, M., and Sironi, M. (2015). The Heptad Repeat Region Is a Major Selection Target in MERS-CoV and Related Coronaviruses. Sci. Rep., 5.","DOI":"10.1038\/srep14480"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/S0140-6736(04)15788-7","article-title":"Interaction between Heptad Repeat 1 and 2 Regions in Spike Protein of SARS-Associated Coronavirus: Implications for Virus Fusogenic Mechanism and Identification of Fusion Inhibitors","volume":"363","author":"Liu","year":"2004","journal-title":"Lancet"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1038\/s41467-025-55824-y","article-title":"Multivalent S2 Subunit Vaccines Provide Broad Protection against Clade 1 Sarbecoviruses in Female Mice","volume":"16","author":"Halfmann","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_137","doi-asserted-by":"crossref","unstructured":"Halfmann, P.J., Frey, S.J., Loeffler, K., Kuroda, M., Maemura, T., Armbrust, T., Yang, J.E., Hou, Y.J., Baric, R., and Wright, E.R. (2022). Multivalent S2-Based Vaccines Provide Broad Protection against SARS-CoV-2 Variants of Concern and Pangolin Coronaviruses. eBioMedicine, 86.","DOI":"10.1016\/j.ebiom.2022.104341"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1016\/j.str.2024.08.022","article-title":"Discovery and Characterization of a Pan-Betacoronavirus S2-Binding Antibody","volume":"32","author":"Johnson","year":"2024","journal-title":"Structure"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/j.immuni.2020.11.015","article-title":"Nanoparticle Vaccines Based on the Receptor Binding Domain (RBD) and Heptad Repeat (HR) of SARS-CoV-2 Elicit Robust Protective Immune Responses","volume":"53","author":"Ma","year":"2020","journal-title":"Immunity"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"3339","DOI":"10.1016\/j.apsb.2023.05.030","article-title":"HR121 Targeting HR2 Domain in S2 Subunit of Spike Protein Can Serve as a Broad-Spectrum SARS-CoV-2 Inhibitor via Intranasal Administration","volume":"13","author":"Lu","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1038\/s41422-022-00746-3","article-title":"A Variant-Proof SARS-CoV-2 Vaccine Targeting HR1 Domain in S2 Subunit of Spike Protein","volume":"32","author":"Pang","year":"2022","journal-title":"Cell Res."},{"key":"ref_142","doi-asserted-by":"crossref","unstructured":"Evtushenko, E., Ryabchevskaya, E., Kovalenko, A., Granovskiy, D., Arkhipenko, M., Vasiliev, Y., Nikitin, N., and Karpova, O. (2024). Wuhan Sequence-Based Recombinant Antigens Expressed in E. Coli Elicit Antibodies Capable of Binding with Omicron S-Protein. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25169016"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"109158","DOI":"10.1016\/j.dib.2023.109158","article-title":"V Dataset on Safety and Protective Efficacy Studies of COVID-19 Vaccine Candidates Based on Structurally Modified Plant Virus in Female Hamsters","volume":"48","author":"Kovalenko","year":"2023","journal-title":"Data Br."},{"key":"ref_144","doi-asserted-by":"crossref","unstructured":"Wang, W.-C., Sayedahmed, E.E., Sambhara, S., and Mittal, S.K. (2022). Progress towards the Development of a Universal Influenza Vaccine. Viruses, 14.","DOI":"10.3390\/v14081684"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"e0151624","DOI":"10.1128\/jvi.01516-24","article-title":"SARS-CoV-2 S Protein Disrupts the Formation of ISGF3 Complex through Conserved S2 Subunit to Antagonize Type I Interferon Response","volume":"99","author":"Cai","year":"2025","journal-title":"J. Virol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"4105","DOI":"10.7189\/jogh.15.04105","article-title":"Comparison of Excess Deaths and Laboratory-Confirmed COVID-19 Deaths during a Large Omicron Epidemic in 2022 in Hong Kong","volume":"15","author":"Xin","year":"2025","journal-title":"J. Glob. Health"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1016\/j.scib.2023.09.048","article-title":"Classification of Five SARS-CoV-2 Serotypes Based on RBD Antigenicities","volume":"68","author":"Hu","year":"2023","journal-title":"Sci. Bull."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/s41579-022-00708-x","article-title":"Towards SARS-CoV-2 Serotypes?","volume":"20","author":"Schwartz","year":"2022","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_149","doi-asserted-by":"crossref","unstructured":"Hou, M., Shi, J., Gong, Z., Wen, H., Lan, Y., Deng, X., Fan, Q., Li, J., Jiang, M., and Tang, X. (2023). Intra- vs. Interhost Evolution of SARS-CoV-2 Driven by Uncorrelated Selection\u2014The Evolution Thwarted. Mol. Biol. Evol., 40.","DOI":"10.1093\/molbev\/msad204"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1016\/j.csbj.2025.03.044","article-title":"Predicting Pathogen Evolution and Immune Evasion in the Age of Artificial Intelligence","volume":"27","author":"Hamelin","year":"2025","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s12985-025-02727-5","article-title":"Tradeoffs between Proliferation and Transmission in Virus Evolution\u2013 Insights from Evolutionary and Functional Analyses of SARS-CoV-2","volume":"22","author":"Tai","year":"2025","journal-title":"Virol. J."},{"key":"ref_152","doi-asserted-by":"crossref","unstructured":"Nielsen, B.F., Saad-Roy, C.M., Li, Y., Sneppen, K., Simonsen, L., Viboud, C., Levin, S.A., and Grenfell, B.T. (2023). Host Heterogeneity and Epistasis Explain Punctuated Evolution of SARS-CoV-2. PLOS Comput. Biol., 19.","DOI":"10.1371\/journal.pcbi.1010896"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"547","DOI":"10.3201\/eid2702.203794","article-title":"SARS-CoV-2 Transmission between Mink (Neovison Vison) and Humans, Denmark","volume":"27","author":"Hammer","year":"2021","journal-title":"Emerg. Infect. Dis."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.eehl.2023.09.004","article-title":"SARS-CoV-2 Infection in Animals: Patterns, Transmission Routes, and Drivers","volume":"3","author":"Fang","year":"2024","journal-title":"Eco-Environ. Health"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"e235","DOI":"10.1016\/S2666-5247(23)00336-1","article-title":"SARS-CoV-2 Shedding and Evolution in Patients Who Were Immunocompromised during the Omicron Period: A Multicentre, Prospective Analysis","volume":"5","author":"Raglow","year":"2024","journal-title":"Lancet Microbe"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"e00110-24","DOI":"10.1128\/mbio.00110-24","article-title":"SARS-CoV-2 Evolution during Prolonged Infection in Immunocompromised Patients","volume":"15","author":"Marques","year":"2024","journal-title":"MBio"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"4287","DOI":"10.1002\/jmv.27885","article-title":"A Bivalent Vaccine Containing D614G and BA.1 Spike Trimer Proteins or a BA.1 Spike Trimer Protein Booster Shows Broad Neutralizing Immunity","volume":"94","author":"Du","year":"2022","journal-title":"J. Med. Virol."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s43856-024-00675-9","article-title":"Beta-Variant Recombinant SARS CoV-2 Vaccine Induces Durable Cross-Reactive Antibodies against Omicron BA Variants","volume":"5","author":"Launay","year":"2025","journal-title":"Commun. Med."},{"key":"ref_159","doi-asserted-by":"crossref","unstructured":"Park, H.-S., Matsuoka, Y., Santos, C., Luongo, C., Liu, X., Yang, L., Kaiser, J.A., Duncan, E.F., Johnson, R.F., and Teng, I.-T. (2025). Intranasal Parainfluenza Virus-Vectored Vaccine Expressing SARS-CoV-2 Spike Protein of Delta or Omicron B.1.1.529 Induces Mucosal and Systemic Immunity and Protects Hamsters against Homologous and Heterologous Challenge. PLoS Pathog., 21.","DOI":"10.1101\/2024.09.12.612598"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"127045","DOI":"10.1016\/j.vaccine.2025.127045","article-title":"Immunogenicity and Safety of Monovalent and Bivalent SARS-CoV-2 Variant Adapted RBD-Based Protein Booster Vaccines in Adults Previously Immunized with Different Vaccine Platforms: A Phase II\/III, Randomized Clinical Trial","volume":"54","author":"Coria","year":"2025","journal-title":"Vaccine"},{"key":"ref_161","doi-asserted-by":"crossref","unstructured":"Ao, D., Peng, D., He, C., Ye, C., Hong, W., Huang, X., Lu, Y., Shi, J., Zhang, Y., and Liu, J. (2025). Correction: A Promising MRNA Vaccine Derived from the JN.1 Spike Protein Confers Protective Immunity against Multiple Emerged Omicron Variants. Mol. Biomed., 6.","DOI":"10.1186\/s43556-025-00260-z"},{"key":"ref_162","doi-asserted-by":"crossref","unstructured":"Piano Mortari, E., Ferrucci, F., Zografaki, I., Carsetti, R., and Pacelli, L. (2025). T and B Cell Responses in Different Immunization Scenarios for COVID-19: A Narrative Review. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1535014"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/s41541-025-01095-z","article-title":"SARS-CoV-2 Infection Primes Cross-Protective Respiratory IgA in a MyD88- and MAVS-Dependent Manner","volume":"10","author":"Kobayashi","year":"2025","journal-title":"Npj Vaccines"},{"key":"ref_164","doi-asserted-by":"crossref","unstructured":"Saha, A., Ghosh Roy, S., Dwivedi, R., Tripathi, P., Kumar, K., Nambiar, S.M., and Pathak, R. (2025). Beyond the Pandemic Era: Recent Advances and Efficacy of SARS-CoV-2 Vaccines Against Emerging Variants of Concern. Vaccines, 13.","DOI":"10.3390\/vaccines13040424"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"e170681","DOI":"10.1172\/jci.insight.170681","article-title":"Combined Anti-S1 and Anti-S2 Antibodies from Hybrid Immunity Elicit Potent Cross-Variant ADCC against SARS-CoV-2","volume":"8","author":"Grant","year":"2023","journal-title":"JCI Insight"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1134\/S0026893323020036","article-title":"On Immunological Studies at Sirius University of Science and Technology","volume":"57","author":"Astrakhantseva","year":"2023","journal-title":"Mol. Biol."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1126\/science.abd0826","article-title":"Structure-Based Design of Prefusion-Stabilized SARS-CoV-2 Spikes","volume":"369","author":"Hsieh","year":"2020","journal-title":"Science"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1021\/acscentsci.1c00080","article-title":"Native-like SARS-CoV-2 Spike Glycoprotein Expressed by ChAdOx1 NCoV-19\/AZD1222 Vaccine","volume":"7","author":"Watanabe","year":"2021","journal-title":"ACS Cent. Sci."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/s41586-020-2665-2","article-title":"Structures and Distributions of SARS-CoV-2 Spike Proteins on Intact Virions","volume":"588","author":"Ke","year":"2020","journal-title":"Nature"},{"key":"ref_170","doi-asserted-by":"crossref","unstructured":"Kordyukova, L.V., Moiseenko, A.V., Serebryakova, M.V., Shuklina, M.A., Sergeeva, M.V., Lioznov, D.A., and Shanko, A. (2023). V Structural and Immunoreactivity Properties of the SARS-CoV-2 Spike Protein upon the Development of an Inactivated Vaccine. Viruses, 15.","DOI":"10.3390\/v15020480"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"e70000","DOI":"10.1111\/imr.70000","article-title":"A Structural Voyage Toward the Landscape of Humoral and Cellular Immune Escapes of SARS-CoV-2","volume":"330","author":"Liu","year":"2025","journal-title":"Immunol. Rev."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/13\/7\/761\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:11:04Z","timestamp":1760033464000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/13\/7\/761"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,17]]},"references-count":171,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["vaccines13070761"],"URL":"https:\/\/doi.org\/10.3390\/vaccines13070761","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,17]]}}}